With Another Warning, FDA Pledges Report On CBD Use In Non-drug Products

 
• By Malcolm Spicer

CBD claim warning comes as FDA reviews more than 4,200 comments on its initiative to determine whether to open regulatory paths for firms to market non-drug products containing hemp- or cannabis-derived ingredients. From Deputy Commissioner Abernethy statement included in announcement about warning, it appears agency is getting message industry trade groups stated in comments that enforcement over non-drug products containing CBD cannot wait.

Curaleaf Patch
FDA found CBD-contaning transdermal patches and other products offered by Curaleaf with disease claims and with other violations of agency regulations.

More from Regulation

More from Policy & Regulation